The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease

Kidney International

Volumn 83, Issue 6, 2013, Pages 1010-1016

  Anders, Hans Joachim ^a   Andersen, Kirstin ^a   Stecher, Bärbel ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

C reactive protein; cytokines; Flora; Innate immunity; Lipopolysaccharide; Malnutrition

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; DEFENSIN; ENDOTOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; IRON; PENTRAXIN 3; PHOSPHATE BINDING AGENT; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; HEMODIALYSIS; HUMAN; HYPERVOLEMIA; IMMUNE DEFICIENCY; IMMUNOREGULATION; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE ISCHEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MEMORY CELL; METABOLIC ACIDOSIS; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; SEPSIS; UREMIA;

EID: 84882241031     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.440     Document Type: Short Survey

References (66)

1. Cerf-Bensussan N, Eberl G. The dialog between microbiota and the immune system: shaping the partners through development and evolution. Semin Immunol 2012; 24: 1-2.
2. Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
3. Tlaskalova-Hogenova H, Stepankova R, Kozakova H et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011; 8: 110-120.
4. Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol 2011; 30: 149-173.
5. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012; 336: 1268-1273.
6. Lam V, Su J, Koprowski S et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 2012; 26: 1727-1735.
7. Sekirov I, Russell SL, Antunes LC et al. Gut microbiota in health and disease. Physiol Rev 2010; 90: 859-904.
8. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010; 31: 817-844.
9. Sandek A, Rauchhaus M, Anker SD et al. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care 2008; 11: 632-639.
10. Evenepoel P, Meijers BK, Bammens BR et al. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009; S12-S19.
11. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-323.
12. Lathrop SK, Bloom SM, Rao SM et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 2011; 478: 250-254.
13. Ivanov II, Atarashi K, Manel N et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-498.
14. Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol 2011; 23: 473-480.
15. Sansonetti PJ. Host-bacteria homeostasis in the healthy and inflamed gut. Curr Opin Gastroenterol 2008; 24: 435-439.
16. Stecher B, Robbiani R, Walker AW et al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol 2007; 5: 2177-2189.
17. Ayres JS, Trinidad NJ, Vance RE. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med 2012; 18: 799-806.
18. Elinav E, Strowig T, Kau AL et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745-757.
19. Vaziri ND, Wong J, Pahl M et al. Chronic kidney disease alters the composition of intestinal microbial flora. Kidney Int 2012 doi:10.1038/ki.2012. 345. (e-pub ahead of print).
20. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol 2011; 12: 5-9.
21. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.
22. Stenvinkel P. Inflammation in end-stage renal disease-a fire that burns within. Contrib Nephrol 2005; 149: 185-199.
23. Kato S, Chmielewski M, Honda H et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 1526-1533.
24. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C et al. The pathogenesis of sepsis. Annu Rev Pathol 2011; 6: 19-48.
25. Heine GH, Ortiz A, Massy ZA et al. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 2012; 8: 362-369.
26. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial 2010; 23: 498-509.
27. Schepers E, Glorieux G, Vanholder R. The gut: the forgotten organ in uremia? Blood Purif 2010; 29: 130-136.
28. Kotanko P, Carter M, Levin NW. Intestinal bacterial microflora-a potential source of chronic inflammation in patients with chronic kidney disease. Nephrol Dial Transplant 2006; 21: 2057-2060.
29. Wen L, Ley RE, Volchkov PY et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008; 455: 1109-1113.
30. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 2004; 4: 478-485.
31. Kranich J, Maslowski KM, Mackay CR. Commensal flora and the regulation of inflammatory and autoimmune responses. Semin Immunol 2011; 23: 139-145.
32. Niebauer J, Volk HD, Kemp M et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353: 1838-1842.
33. Wang F, Zhang P, Jiang H et al. Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci 2012.
34. McIntyre CW, Harrison LE, Eldehni MT et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 133-141.
35. Clarke TB, Davis KM, Lysenko ES et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010; 16: 228-231.
36. Lee YK, Menezes JS, Umesaki Y et al. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2011; 108(Suppl 1): 4615-4622.
37. Anders HJ. Innate pathogen recognition in the kidney: toll-like receptors, NOD-like receptors, and RIG-like helicases. Kidney Int 2007; 72: 1051-1056.
38. Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192.
39. Ryu M, Kulkarni OP, Radomska E et al. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-alpha-mediated podocyte loss. Kidney Int 2011; 79: 189-198.
40. Patole PS, Pawar RD, Lichtnekert J et al. Coactivation of Toll-like receptor-3 and-7 in immune complex glomerulonephritis. J Autoimmun 2007; 29: 52-59.
41. Aronov PA, Luo FJ, Plummer NS et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 2011; 22: 1769-1776.
42. Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007; 357: 1316-1325.
43. Ranganathan N, Patel BG, Ranganathan P et al. In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J 2006; 52: 70-79.
44. Niwa T. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial 2011; 15: 120-124.
45. Ueda H, Shibahara N, Takagi S et al. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008; 30: 856-860.
46. Anders HJ, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol 2011; 22: 1007-1018.
47. Vaziri ND, Pahl MV, Crum A et al. Effect of uremia on structure and function of immune system. J Ren Nutr 2012; 22: 149-156.
48. Janus N, Vacher LV, Karie S et al. Vaccination and chronic kidney disease. Nephrol Dial Transplant 2008; 23: 800-807.
49. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009; 30: 475-487.
50. Hotchkiss RS, Coopersmith CM, McDunn JE et al. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009; 15: 496-497.
51. Zhang LT, Yao YM, Lu JQ et al. Sodium butyrate prevents lethality of severe sepsis in rats. Shock 2007; 27: 672-677.
52. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Sem Nephrol 2004; 24: 469-473.
53. Alexiewicz JM, Smogorzewski M, Fadda GZ et al. Impaired phagocytosis in dialysis patients: studies on mechanisms. Am J Nephrol 1991; 11: 102-111.
54. Girndt M, Sester M, Sester U et al. Molecular aspects of T-and B-cell function in uremia. Kidney Int Suppl 2001; 78: S206-S211.
55. Massry S, Smogorzewski M. Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone. Kidney Int Suppl 2001; 78: S195-S196.
56. Yoon JW, Pahl MV, Vaziri ND. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 2007; 71: 167-172.
57. Beaman M, Michael J, MacLennan IC et al. T-cell-independent and T-celldependent antibody responses in patients with chronic renal failure. Nephrol Dial Transplant 1989; 4: 216-221.
58. Meuer SC, Hauer M, Kurz P et al. Selective blockade of the antigenreceptor-mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest 1987; 80: 743-749.
59. Pahl MV, Gollapudi S, Sepassi L et al. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010; 25: 205-212.
60. Sester U, Sester M, Hauk M et al. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1217-1223.
61. Hesselink DA, Betjes MGH, Verkade MA et al. The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. Nephrol Dial Transplant 2005; 20: 1868-1873.
62. Verkade MA, van Druningen CJ, Vaessen LMB et al. Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease. Nephrol Dial Transplant 2007; 22: 128-138.
63. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298: F662-F671.
64. Matsumoto Y, Shinzato T, Amano I et al. Relationship between susceptibility to apoptosis and Fas expression in peripheral blood T cells from uremic patients: a possible mechanism for lymphopenia in chronic renal failure. Biochem Biophys Res Commun 1995; 215: 98-105.
65. Moser B, Roth G, Brunner M et al. Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: a comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. Biochem Biophys Res Commun 2003; 308: 581-585.
66. Yoon JW, Gollapudi S, Pahl MV et al. Näve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 2006; 70: 371-376.